{"id":373826,"date":"2023-12-08T05:23:21","date_gmt":"2023-12-08T10:23:21","guid":{"rendered":"https:\/\/platohealth.ai\/abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics\/"},"modified":"2023-12-09T11:25:40","modified_gmt":"2023-12-09T16:25:40","slug":"abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics\/","title":{"rendered":"AbbVie to buy neuroscience specialist Cerevel Therapeutics","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
AbbVie plans to acquire neuroscience specialist Cerevel Therapeutics for $45 per share, or around $8.7 billion.<\/p>\n<\/div>\n
AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline \u2013 including antipsychotic emraclidine \u2013 for approximately $8.7 billion.<\/p>\n
Cerevel\u2019s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson\u2019s disease, and mood disorders.<\/p>\n
AbbVie said the acquisition complements its neuroscience portfolio, adding a range of assets with potential across psychiatric and neurological disorders with unmet need.<\/p>\n
\u201cOur existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade,\u201d commented Richard A. Gonzalez, chairman and chief executive officer of AbbVie.<\/p>\n
As part of the deal AbbVie will acquire antipsychotic emraclidine, which is currently in Phase II trials<\/a> for schizophrenia and has potential in dementia-related psychosis in Alzheimer\u2019s and Parkinson\u2019s diseases.<\/p>\n Emraclidine is a positive allosteric modulator (PAM) of the muscarinic M4 receptor. The drug has shown promising efficacy and safety in a Phase Ib study for schizophrenia. A Phase I study of emraclidine is also underway in in elderly healthy volunteers in support of a potential Alzheimer\u2019s disease psychosis programme.<\/p>\n Cerevel\u2019s other neuroscience assets in clinical development include:<\/p>\n FDA approves first-in-class antidepressant<\/a><\/p>\n<\/blockquote>\n This is the third acquisition announced by AbbVie this quarter. The transaction is expected to close in the middle of 2024, subject to Cerevel shareholder approval, regulatory approvals, and other customary closing conditions.\u00a0<\/p>\n In October, AbbVie completed the acquisition of Mitokinin, a discovery-stage neuroscience company. Mitokinin is developing a selective PINK1 activator, designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson\u2019s disease pathogenesis and progression.<\/p>\n AbbVie also agreed a $10.1 billion deal to acquire ImmunoGen<\/a> and its antibody-drug conjugate ELAHERE \u00ae (mirvetuximab soravtansine-gynx), which is approved for platinum-resistant ovarian cancer (PROC).<\/p>\n AbbVie plans to acquire neuroscience specialist Cerevel Therapeutics for $45 per share, or around $8.7 billion. AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline \u2013 including antipsychotic emraclidine \u2013 for approximately $8.7 billion. Cerevel\u2019s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson\u2019s […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":373830,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/373826"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=373826"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/373826\/revisions"}],"predecessor-version":[{"id":373829,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/373826\/revisions\/373829"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/373830"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=373826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=373826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=373826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
AbbVie\u2019s recent acquisitions<\/h2>\n
\n